Skip to main content

Labcorp Message (as of July 21, 4:00 p.m. ET)

  • All Labcorp core systems impacted by the CrowdStrike issues are currently back online.
  • Some of our patient service centers and in-office labs may be experiencing technical issues with retrieving orders.
  • We are working hard to resolve this issue.
  • If you have a copy of your order, this will help expedite the process.
  • We appreciate your patience as we work to restore business operations.

Specialized scientific experience to accelerate your cell therapy program

Cell therapies

Key insights and customized support to minimize potential risks
  • Comprehensive global experience supporting of 6 FDA-approved CAR T-cell therapies

  • Novel platforms and approaches critical to advanced therapy development, including NGS, single-cell sequencing, digital spatial profiling and mass cytometry

  • Focused preclinical discovery and precision oncology product portfolio for solid tissue, liquid biopsy, and immune profiling

A partner for your adoptive cell therapy testing needs—wherever you are in development

Adoptive cell therapies (ACTs) can deliver transformative approaches to patient care. Whether you are working with tumor-infiltrating lymphocytes, gene-modified T-cells expressing novel T-cell receptors, chimeric antigen receptor T-cells (CAR T) or CAR natural killer cells, we can support your laboratory assessments across the entire development continuum.


In vitro analysis

  • Transduction efficiency (flow cytometry)
  • Cytotoxicity analysis and multiplex release assays
  • PBMC subset isolation and cell activation
  • Cell-based functional assays
  • Karyology
  • Tissue cross-reactivity

Pharmacodynamic (PD) response/efficacy

  • Oncology models for PD/efficacy
  • ACT tumor infiltration by immunohistochemistry
  • Broad-scale gene expression profiling (RNA-Seq NanoString)
  • Flow cytometry analysis, immunoassay and VCN measurement

Toxicology and safety assessment

  • GLP tumor/non-tumor-bearing in vivo studies (multiple species)
  • GLP formulation, dose analysis, administration
  • Biodistribution and persistence by flow cytometry, qPCR or ddPCR
  • Histopathology and IHC
  • Cytokine/chemokine analysis: multiplexed immunoassays
  • Clinical Pathology (e.g., clinical chemistry, hematology)
  • Toxicology for Phase I doses 

Critical quality attributes

  • Vector copy number, titer and viability
  • Potency and biological activity
  • Safety and RCL/RCR
  • Purity and impurities
  • Identity
  • Stability

PD response/efficacy

  • Cell persistence and expansion by qPCR/ddPCR and flow cytometry
  • Tumor and immune cell profiling
  • Immunophenotyping by flow cytometry (T-cell lineage, B-cells, memory T-cells, Treg)
  • ELISpot analysis
  • IHC, NanoString DSP
  • Gene expression profiling (NanoString, RNA-Seq, NGS)
  • T-cell clonality
  • Minimal residual disease assessment (flow cytometry, NGS)
  • PD effect on cytokines, chemokines and growth factors (Luminex, MSD, Quanterix, ELISA)


  • Cytokine release syndrome-mediated cytokine and inflammatory
    mediators by multiplexed immunoassay approach (Luminex, MSD)
  • Karyotype
  • RCR/RCL by PCR

Target identification and patient selection/predictive biomarkers

  • Target antigen expression by IHC or gene expression
  • HLA analysis
  • Transcriptomic analysis and signature definition for evaluating tumor microenvironment and immune function (OmniSeq Insight)
  • Mutational and epigenetic analysis by NGS 


Providing you the laboratory expertise and global scale you need—with the personalized experience you deserve.